TrialJournal for immunotherapy of cancer2021

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).

Michael J Wagner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.